nach oben

Reactions Weekly

Erschienen in:

01.04.2021 | Case report

Ipilimumab/nivolumab/relatlimab

Hyperprogression of metastatic vaginal melanoma and myocarditis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Auszug

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Barham W, et al. Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology 11: 2020. Available from: URL: http://doi.org/10.3389/fimmu.2020.561083

Titel: Ipilimumab/nivolumab/relatlimab
Hyperprogression of metastatic vaginal melanoma and myocarditis: case report
Publikationsdatum: 01.04.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-94701-z

Benralizumab/ciclosporin

Case report

Antineoplastics/cefazolin

Case report

Interferon-beta-1a

Case report

Multiple drugs

Case report

Ustekinumab

Case report

Anti-PD-1-induced cardiac events in patients with melanoma

Clinical study

Springer Medizin

Ipilimumab/nivolumab/relatlimab

Hyperprogression of metastatic vaginal melanoma and myocarditis: case report

Auszug

Weitere Artikel der Ausgabe 1/2021

Benralizumab/ciclosporin

Antineoplastics/cefazolin

Interferon-beta-1a

Multiple drugs

Ustekinumab

Anti-PD-1-induced cardiac events in patients with melanoma

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Benralizumab/ciclosporin

Antineoplastics/cefazolin

Interferon-beta-1a

Multiple drugs

Ustekinumab

Anti-PD-1-induced cardiac events in patients with melanoma